Gilead Sciences

YTD

ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

CEO

Daniel P. O'Day

CEODaniel P. O'Day

Employees

17,000

Employees17,000

Headquarters

Foster City, California

HeadquartersFoster City, California

Founded

1987

Founded1987

Employees

17,000

Employees17,000

GILD Key Statistics

Market cap

181.76B

Market cap181.76B

Price-Earnings ratio

-56.84

Price-Earnings ratio-56.84

Dividend yield

2.13%

Dividend yield2.13%

Average volume

5.21M

Average volume5.21M

High today

$149.50

High today$149.50

Low today

$145.45

Low today$145.45

Open price

$146.98

Open price$146.98

Volume

1.62M

Volume1.62M

52 Week high

$157.29

52 Week high$157.29

52 Week low

$108.46

52 Week low$108.46

Stock Snapshot

With a market cap of 181.76B, Gilead Sciences(GILD) trades at $146.59. The stock has a price-to-earnings ratio of -56.84 and currently yields dividends of 2.13%.

As of 2026-09-08, Gilead Sciences(GILD) stock has fluctuated between $145.45 and $149.50. The current price stands at $146.59, placing the stock +0.8% above today's low and -1.9% off the high.

Gilead Sciences(GILD) shares are trading with a volume of 1.62M, against a daily average of 5.21M.

During the past year, Gilead Sciences(GILD) stock moved between $108.46 at its lowest and $157.29 at its peak.

GILD News

Nasdaq 3d

Gilead Sciences Just Won Its Third FDA Approval in Less Than 4 Months. Is the Stock Still Underrating This Turnaround Play?

Key Points Gilead is best known for its dominant HIV franchise. But the company has been actively diversifying via acquisitions. The biotech has raised its q...

24/7 Wall St. 4d

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Investing Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them? Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot...

TipRanks 5d

Gilead’s Arcus-Backed Cancer Trial Reaches Completion, Setting Up a Key Immuno-Oncology Catalyst

Gilead Sciences (GILD) announced an update on their ongoing clinical study. Gilead Partner Study Marks Milestone in First-Line Stomach Cancer Therapy. This Phas...

Analyst ratings

77%

of 30 ratings

Buy

76.7%

Hold

20%

Sell

3.3%

More GILD News

Simply Wall St 6d

Is Gilead Sciences Fully Valued On Its New HIV And Cancer Drug Approvals?

Gilead Sciences (GILD) has drawn fresh investor attention after two recent regulatory decisions. The FDA approved Bixlenvo for virologically suppressed adults w...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

WisdomTree Japan Hedged E…

Cadence Design Systems

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.